psoriasis epidemiology screening tool |
483 |
psoriasis |
483 |
psoriatic arthritis |
483 |
screening questionnaire. |
483 |
ankle-brachial index |
495 |
carotid intima-media thickness |
495 |
heart disease risk factors |
495 |
systemic lupus erythematosus |
495, 527 |
vascular stiffness. |
495 |
cytochrome c oxidase subunits 1 |
504 |
malondialdehyde |
504 |
oxidative stress |
504 |
systemic lupus erythematosus. |
504, 566, 626 |
carpal tunnel syndrome |
517 |
steroid phonophoresis |
517 |
ultrasound. |
517 |
disease activity |
527, 593 |
lupus nephritis |
527 |
urinary plasmin. |
527 |
gouty arthritis |
536 |
inflammation |
536 |
mirna-23a-5p |
536 |
myd88 |
536 |
nf-&kappa |
536 |
b |
536 |
tlr2. |
536 |
clinical examination |
547 |
juvenile idiopathic arthritis |
547 |
magnetic resonance imaging |
547 |
shoulder joint. |
547 |
coronaphobia |
559 |
physical activity |
559 |
rheumatoid arthritis. |
559 |
complement receptor 2 |
566 |
mutation |
566 |
sequencing |
566 |
cervical radiculopathy |
574 |
disability evaluation |
574 |
herniated disc |
574 |
pain measurement |
574 |
questionnaire. |
574 |
dyslipidemia |
584 |
gene polymorphism |
584 |
low-density lipoprotein cholesterol |
584 |
lupus |
584 |
nephritis. |
584 |
abnormal lipid level |
593 |
insulin resistance |
593 |
very early rheumatoid arthritis. |
593 |
kinesiophobia |
603 |
remission |
603 |
rheumatoid arthritis |
603, 613 |
pain |
603 |
physical activity. |
603 |
etanercept |
613 |
genetic polymorphism |
613 |
response |
613 |
tumor necrosis factor-alpha. |
613 |
anti-double-stranded deoxyribonucleic acid |
626 |
antinuclear antibody |
626 |
antiphospholipid antibody |
626 |
complement |
626 |